EA201891120A1 - 1,3-тиазол-2-ил замещенные бензамиды - Google Patents

1,3-тиазол-2-ил замещенные бензамиды

Info

Publication number
EA201891120A1
EA201891120A1 EA201891120A EA201891120A EA201891120A1 EA 201891120 A1 EA201891120 A1 EA 201891120A1 EA 201891120 A EA201891120 A EA 201891120A EA 201891120 A EA201891120 A EA 201891120A EA 201891120 A1 EA201891120 A1 EA 201891120A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
tiazol
substituted benzamides
thiazol
disease
Prior art date
Application number
EA201891120A
Other languages
English (en)
Other versions
EA034273B1 (ru
Inventor
Адам Джеймс Дейвенпорт
Нико Бройер
Оливер Мартин Фишер
Андреа Ротгери
Антье Роттманн
Иоана Неагоэ
Йенс Нагель
Анне-Мари Годино-Коэло
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891120(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA201891120A1 publication Critical patent/EA201891120A1/ru
Publication of EA034273B1 publication Critical patent/EA034273B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к 1,3-тиазол-2-ил замещенным бензамидным соединениям общей формулы (I), как описано и определено в настоящей заявке, к фармацевтическим композициям и комбинациям, содержащим указанные соединения, и к применению указанных соединений для производства фармацевтической композиции для лечения или профилактики заболевания, в частности нейрогенного нарушения, в виде единственного средства или в комбинации с другими активными компонентами.
EA201891120A 2014-12-09 2015-12-07 1,3-тиазол-2-ил замещенные бензамиды EA034273B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09

Publications (2)

Publication Number Publication Date
EA201891120A1 true EA201891120A1 (ru) 2018-10-31
EA034273B1 EA034273B1 (ru) 2020-01-23

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791261A EA032312B1 (ru) 2014-12-09 2015-12-07 1,3-тиазол-2-ил замещенные бензамиды
EA201891120A EA034273B1 (ru) 2014-12-09 2015-12-07 1,3-тиазол-2-ил замещенные бензамиды

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791261A EA032312B1 (ru) 2014-12-09 2015-12-07 1,3-тиазол-2-ил замещенные бензамиды

Country Status (41)

Country Link
US (5) US10174016B2 (ru)
EP (2) EP3587417B9 (ru)
JP (2) JP6544665B2 (ru)
KR (2) KR20230098368A (ru)
CN (2) CN107207507B (ru)
AR (2) AR102948A1 (ru)
AU (1) AU2015359626B2 (ru)
BR (1) BR112017012327B1 (ru)
CA (1) CA2969952A1 (ru)
CL (1) CL2017001488A1 (ru)
CO (1) CO2017005742A2 (ru)
CR (2) CR20170242A (ru)
CU (1) CU24411B1 (ru)
CY (2) CY1124486T1 (ru)
DK (2) DK3230281T3 (ru)
DO (2) DOP2017000137A (ru)
EA (2) EA032312B1 (ru)
EC (1) ECSP17036253A (ru)
ES (2) ES2908822T3 (ru)
HR (2) HRP20220371T1 (ru)
HU (2) HUE055290T2 (ru)
IL (6) IL252665B (ru)
JO (1) JOP20150301B1 (ru)
LT (2) LT3230281T (ru)
MA (2) MA50674B1 (ru)
MX (2) MX2017007658A (ru)
MY (1) MY192690A (ru)
NI (1) NI201700073A (ru)
PE (2) PE20220253A1 (ru)
PH (1) PH12017501079A1 (ru)
PL (2) PL3587417T3 (ru)
PT (2) PT3587417T (ru)
RS (2) RS62227B1 (ru)
SG (2) SG10202012274RA (ru)
SI (2) SI3587417T1 (ru)
SV (1) SV2017005461A (ru)
TN (1) TN2017000244A1 (ru)
TW (2) TWI716371B (ru)
UA (1) UA120382C2 (ru)
UY (1) UY36422A (ru)
WO (1) WO2016091776A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62227B1 (sr) * 2014-12-09 2021-09-30 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
JOP20200286A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
SG11202011018PA (en) * 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CA3115649A1 (en) 2018-10-05 2020-04-09 Shionogi & Co., Ltd. Medicament for the treatment of chronic cough
KR20210074315A (ko) * 2018-10-10 2021-06-21 벨루스 헬스 코프 인크. P2x3 길항제를 사용한 소양증의 치료
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
CN113661165A (zh) * 2019-04-05 2021-11-16 先正达农作物保护股份公司 杀有害生物活性的二嗪-酰胺化合物
MA55587A (fr) * 2019-04-11 2022-02-16 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
AU2020281924A1 (en) 2019-05-31 2021-12-16 Chiesi Farmaceutici S.P.A. Pyridopyrimidines derivatives as P2X3 inhibitors
CN113891745B (zh) 2019-05-31 2024-05-07 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (zh) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 芳甲酰胺类化合物及其制备方法和医药用途
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
IL301667A (en) 2020-09-30 2023-05-01 Humanwell Healthcare Group Co Ltd Benzamide compound and its use
WO2022112493A1 (en) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. Phthalazine derivatives as p2x3 inhibitors
KR20230113536A (ko) 2020-11-27 2023-07-31 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 (아자)퀴놀린 4-아민 유도체
CA3196333A1 (en) 2020-11-27 2022-06-02 Claudio FIORELLI Amino quinazoline derivatives as p2x3 inhibitors
WO2022253943A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
TW202404965A (zh) * 2022-03-29 2024-02-01 大陸商人福醫藥集團股份公司 P2x3抑制劑化合物及其鹽、多晶型和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
ES2604542T3 (es) 2006-06-29 2017-03-07 F. Hoffmann-La Roche Ag Arilamidas con sustitución tetrazol
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
BRPI0718714B8 (pt) * 2006-11-09 2021-05-25 Hoffmann La Roche arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
US20090317360A1 (en) * 2007-06-12 2009-12-24 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト
WO2009058299A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3 receptor antagonists for treatment of pain
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
ES2570628T3 (es) 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
JP5456691B2 (ja) 2007-12-17 2014-04-02 エフ.ホフマン−ラ ロシュ アーゲー テトラゾール置換されたアリールアミド誘導体ならびにp2x3及び/又はp2x2/3プリン作動性受容体アンタゴニストとしてのその使用
AU2008337660B2 (en) 2007-12-17 2014-02-06 F. Hoffmann-La Roche Ag Triazole-substituted arylamide derivatives and their use as P2X3 and /or P2X2/3 purinergic receptor antagonists
CA2715835C (en) * 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
EP2860178B1 (en) * 2008-10-31 2021-01-13 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
WO2010069794A1 (en) 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Thiadiazole-substituted arylamides
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
SG176640A1 (en) 2009-06-22 2012-01-30 Hoffmann La Roche Novel oxazolone and pyrrolidinone-substituted arylamides
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
US9562041B2 (en) * 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
TR201807602T4 (tr) 2013-01-31 2018-06-21 Neomed Inst İmidazopiridin bileşikleri ve bunların kullanımları.
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RS62227B1 (sr) * 2014-12-09 2021-09-30 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
JOP20200286A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

Also Published As

Publication number Publication date
TW201629053A (zh) 2016-08-16
EP3230281A1 (en) 2017-10-18
US11142523B2 (en) 2021-10-12
DOP2017000137A (es) 2017-07-31
CU20170077A7 (es) 2017-11-07
TWI716371B (zh) 2021-01-21
CU24411B1 (es) 2019-05-03
EP3230281B1 (en) 2021-05-26
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
IL283979A (en) 2021-07-29
CN107207507A (zh) 2017-09-26
MA50674A (fr) 2021-03-31
PL3587417T3 (pl) 2022-06-13
IL269661A (en) 2019-11-28
CN110256418B (zh) 2023-01-20
AU2015359626A1 (en) 2017-06-29
ECSP17036253A (es) 2017-06-30
MA41135B1 (fr) 2021-10-29
US10174016B2 (en) 2019-01-08
DK3230281T3 (da) 2021-08-16
PT3230281T (pt) 2021-08-19
PH12017501079A1 (en) 2017-10-18
TW202130637A (zh) 2021-08-16
KR20230098368A (ko) 2023-07-03
IL283979B (en) 2022-04-01
CN107207507B (zh) 2020-11-06
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
SG10202012274RA (en) 2021-01-28
IL269468A (en) 2019-11-28
IL275183B (en) 2021-06-30
EP3587417A1 (en) 2020-01-01
HRP20211002T1 (hr) 2021-09-17
PL3230281T3 (pl) 2021-12-13
EA034273B1 (ru) 2020-01-23
DK3587417T3 (da) 2022-03-28
IL269467A (en) 2019-11-28
IL269661B (en) 2020-07-30
EP3587417B9 (en) 2022-03-30
JP6544665B2 (ja) 2019-07-17
US10472354B2 (en) 2019-11-12
HUE058009T2 (hu) 2022-06-28
DOP2018000182A (es) 2018-09-15
WO2016091776A1 (en) 2016-06-16
IL275183A (en) 2020-07-30
RS63014B1 (sr) 2022-04-29
IL252665B (en) 2019-10-31
SI3230281T1 (sl) 2021-08-31
ES2908822T3 (es) 2022-05-04
US20190185466A1 (en) 2019-06-20
CL2017001488A1 (es) 2018-02-23
CR20210108A (es) 2021-04-27
JOP20150301B1 (ar) 2023-09-17
MA50674B1 (fr) 2022-11-30
RS62227B1 (sr) 2021-09-30
UA120382C2 (uk) 2019-11-25
JP2019059742A (ja) 2019-04-18
IL252665A0 (en) 2017-08-31
BR112017012327B1 (pt) 2023-04-11
SG11201704717VA (en) 2017-08-30
PE20180227A1 (es) 2018-01-31
KR102548799B1 (ko) 2023-06-27
JP6647371B2 (ja) 2020-02-14
US20180093980A1 (en) 2018-04-05
IL269468B (en) 2020-06-30
LT3230281T (lt) 2021-07-12
KR20170093203A (ko) 2017-08-14
TWI780562B (zh) 2022-10-11
AR102948A1 (es) 2017-04-05
HRP20220371T1 (hr) 2022-05-13
CY1124486T1 (el) 2022-07-22
CY1125083T1 (el) 2023-06-09
CR20170242A (es) 2018-02-02
CA2969952A1 (en) 2016-06-16
HUE055290T2 (hu) 2021-11-29
PT3587417T (pt) 2022-03-16
PE20220253A1 (es) 2022-02-16
EP3587417B1 (en) 2022-01-05
MY192690A (en) 2022-09-01
CO2017005742A2 (es) 2017-09-20
LT3587417T (lt) 2022-02-10
US20200131169A1 (en) 2020-04-30
SI3587417T1 (sl) 2022-04-29
US10202369B2 (en) 2019-02-12
NI201700073A (es) 2017-10-24
JP2017537122A (ja) 2017-12-14
MX2017007658A (es) 2018-08-01
CN110256418A (zh) 2019-09-20
EA032312B1 (ru) 2019-05-31
EA201791261A1 (ru) 2017-12-29
MX2020005909A (es) 2021-10-28
AR119761A2 (es) 2022-01-12
UY36422A (es) 2016-06-30
US20230053411A1 (en) 2023-02-23
ES2882952T3 (es) 2021-12-03
US20180118731A1 (en) 2018-05-03
AU2015359626B2 (en) 2020-07-23
IL269467B (en) 2020-08-31
TN2017000244A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
CU20190045A7 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201790306A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
EA201792421A1 (ru) Амидозамещенные производные циклогексана
DOP2016000253A (es) Nuevos compuestos
EA202090448A1 (ru) Дигидрооксадиазиноны
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
MA39762A (fr) Nouveaux composés

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM